Vivoryon Therapeutics N.V. (AMS:VVY)
Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.130
-0.010 (-0.88%)
Aug 27, 2026, 12:01 PM CET

Vivoryon Therapeutics Financials Overview

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----3.62-10.76
Revenue Growth
------
Gross Profit
----3.1-9.2
Operating Income
-6.78-8.91-20.96-28.84-29.11-12.8
Net Income
-6.77-8.85-20.57-28.34-28.16-12.66
Earnings Per Share
-0.24-0.33-0.79-1.12-1.28-0.63
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
2.455.629.3728.5826.5614.66
Total Debt
0.080.110.10.040.130.22
Net Cash (Debt)
2.375.519.2628.5526.4314.44
Net Cash Growth
-56.99%-40.51%-67.55%8.00%83.07%-44.46%
Net Cash Per Share
0.080.200.361.131.200.72

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-7.1-8.46-19.17-21.54-21.79-11.26
Capital Expenditures
-0-0.01-0-0.01-0.01-0.02
Free Cash Flow
-7.11-8.46-19.18-21.56-21.81-11.28
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----85.42%
Operating Margin
------118.91%
Pretax Margin
---789.39%--113.55%
Profit Margin
------117.57%
FCF Margin
------104.77%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-9.349.349.349.349.34
PS Ratio
----58.61-35.39